Remsima

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:European_Union
gptkb:South_Korea
gptkb:United_States
gptkbp:bioequivalence gptkb:Remicade
gptkbp:class immunomodulator
gptkbp:clinical_trial gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
Phase III trials
gptkbp:contraindication heart failure
active infections
hypersensitivity to infliximab
gptkbp:developed_by gptkb:Celltrion
gptkbp:dosage_form solution for infusion
gptkbp:drug_interactions immunosuppressants
live vaccines
gptkbp:duration varies by condition
gptkbp:effective_date gptkb:2013
gptkbp:events regular monitoring
gptkbp:financial_support available
gptkbp:formulation lyophilized powder
https://www.w3.org/2000/01/rdf-schema#label Remsima
gptkbp:ingredients infliximab
gptkbp:invention patented
gptkbp:is_effective_against demonstrated in studies
gptkbp:launch_date gptkb:2015
gptkbp:manufacturer gptkb:Celltrion_Healthcare
gptkbp:marketed_as multiple countries
biosimilar to Remicade
gptkbp:mechanism_of_action TNF-alpha inhibitor
gptkbp:patient_education important for adherence
gptkbp:patient_population gptkb:children
adults
gptkbp:pharmacovigilance ongoing monitoring
gptkbp:price varies by region
gptkbp:provides_guidance_on included in treatment guidelines
gptkbp:reconstitution_required gptkb:true
gptkbp:regulatory_compliance approved
gptkbp:research_and_development ongoing
gptkbp:route_of_administration intravenous infusion
gptkbp:safety_features well-studied
gptkbp:sales increasing
gptkbp:side_effect headache
nausea
abdominal pain
infections
infusion reactions
gptkbp:storage refrigerated
gptkbp:supply_chain managed by Celltrion
gptkbp:training recommended
gptkbp:used_for treatment of autoimmune diseases
gptkbp:website intravenous
gptkbp:bfsParent gptkb:Celltrion
gptkbp:bfsLayer 6